2026-07-22T03:36:53Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/199962024-11-28T16:36:31Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16958col_20.500.12105_16967
Repisalud
author
Garcia-Delgado, Regina
author
de Miguel, Dunia
author
Bailen, Alicia
author
Ramon Gonzalez, Jose
author
Bargay Lleonart, Joan
author
Falantes, Jose F.
author
Andreu, Rafael
author
Fernando, Ramosh
author
Tormo, Mar
author
Brunet, Salut
author
Figueredo, M. A.
author
Casano, Javier
author
Medina, Angeles
author
Badiella, Llorenc
author
Fernandez Jurado, Antonio
author
Sanz, Guillermo
author
Asociacion Andaluza de Hematologia
2024-07-03T11:09:20Z
2024-07-03T11:09:20Z
2014-07
Garcia-Delgado R, De Miguel D, Bailen A, Ramon Gonzalez J, Bargay Lleonart J, Falantes JF, et al. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia. Leuk Res. 2014 Jul;38(7):744-50. Epub 2014 Mar 19.
10.1016/j.leukres.2014.03.004
0145-2126
Leukemia Research
http://hdl.handle.net/20.500.13003/17327
24795069
L53121904
2-s2.0-84902116204
http://hdl.handle.net/20.500.12105/19996
339339400005
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.
eng
Acute myeloid leukemia
Azacitidine
Dosing schedules
Myelodysplastic syndromes
Overall survival
Safety
Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia
research article